Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Parkinson's Disease

  Free Subscription


1 BMC Neurol
1 Exp Neurol
1 Int J Neurosci
1 J Neurosci
5 Mov Disord
2 Neurobiol Dis
3 Neurology
1 Proc Natl Acad Sci U S A
1 Rev Neurol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Neurol

  1. NICASTRO N, Garibotto V, Burkhard PR
    Extrastriatal (123)I-FP-CIT SPECT impairment in Parkinson's disease - the PPMI cohort.
    BMC Neurol. 2020;20:192.
    PubMed         Abstract available

    Exp Neurol

  2. CINAR E, Yalcin-Cakmakli G, Saka E, Ulusoy A, et al
    Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Exp Neurol. 2020 May 10:113357. doi: 10.1016/j.expneurol.2020.113357.
    PubMed         Abstract available

    Int J Neurosci

  3. CHAUDHARY S, Kumaran SS, Goyal V, Kaloiya GS, et al
    Cortical thickness and gyrification index measuring cognition in Parkinson's disease.
    Int J Neurosci. 2020 May 18:1-10. doi: 10.1080/00207454.2020.1766459.
    PubMed         Abstract available

    J Neurosci

  4. GUERRA A, Asci F, D'Onofrio V, Sveva V, et al
    Enhancing gamma oscillations restores primary motor cortex plasticity in Parkinson's disease.
    J Neurosci. 2020 May 19. pii: JNEUROSCI.0357-20.2020.
    PubMed         Abstract available

    Mov Disord

  5. KIM HJ, Jeon B
    Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?
    Mov Disord. 2020;35:901-902.

  6. BONET-PONCE PHD L, Cookson MR
    Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Mov Disord. 2020;35:721-723.

  7. MILOSEVIC L, Scherer M, Cebi I, Guggenberger R, et al
    Online Mapping with the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28093.
    PubMed         Abstract available

  8. TURNER TH, Dale ML
    Inconsistent Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28108.

  9. SHALASH A, Roushdy T, Essam M, Fathy M, et al
    Mental health, physical activity and quality of life in Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 May 19. doi: 10.1002/mds.28134.

    Neurobiol Dis

  10. HARJUHAAHTO S, Rasila TS, Molchanova SM, Woldegebriel R, et al
    ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human IPSC-derived motor neurons.
    Neurobiol Dis. 2020 May 8:104940. doi: 10.1016/j.nbd.2020.104940.
    PubMed         Abstract available

  11. HEATON GR, Landeck N, Mamais A, Nalls MA, et al
    Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
    Neurobiol Dis. 2020 May 17:104948. doi: 10.1016/j.nbd.2020.104948.
    PubMed         Abstract available


  12. POTTEGARD A, Hopfner F, Wod M, Hoglinger GU, et al
    Author response: Use of beta2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
    Neurology. 2020;94:899.

  13. SCHERZER CR, Riise T, Locascio JJ
    Reader response: Use of beta2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
    Neurology. 2020;94:898-899.

  14. SIEGLER JE 3RD, Galetta S
    Editors' note: Use of beta2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
    Neurology. 2020;94:897-898.

    Proc Natl Acad Sci U S A

  15. CAO M, Park D, Wu Y, De Camilli P, et al
    Absence of Sac2/INPP5F enhances the phenotype of a Parkinson's disease mutation of synaptojanin 1.
    Proc Natl Acad Sci U S A. 2020 May 18. pii: 2004335117.
    PubMed         Abstract available

    Rev Neurol

  16. CHIARAMONTE R, Bonfiglio M
    Acoustic analysis of voice in Parkinson's disease: a systematic review of voice disability and meta-analysis of studies.
    Rev Neurol. 2020;70:393-405.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.